Harbour Investments Inc. Grows Stock Holdings in Omeros Corporation $OMER

Harbour Investments Inc. raised its position in shares of Omeros Corporation (NASDAQ:OMER) by 46.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,469 shares of the biopharmaceutical company’s stock after purchasing an additional 4,251 shares during the period. Harbour Investments Inc.’s holdings in Omeros were worth $40,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in OMER. Wellington Management Group LLP purchased a new stake in Omeros during the first quarter valued at about $1,118,000. Nuveen LLC bought a new position in shares of Omeros during the first quarter valued at about $938,000. Vanguard Group Inc. grew its stake in shares of Omeros by 3.0% during the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company’s stock valued at $26,610,000 after buying an additional 95,599 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Omeros during the first quarter valued at about $579,000. Finally, Invesco Ltd. grew its stake in shares of Omeros by 169.1% during the first quarter. Invesco Ltd. now owns 87,044 shares of the biopharmaceutical company’s stock valued at $716,000 after buying an additional 54,696 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Price Performance

NASDAQ OMER opened at $7.55 on Friday. The stock has a market capitalization of $513.85 million, a PE ratio of -3.58 and a beta of 2.32. Omeros Corporation has a 1 year low of $2.95 and a 1 year high of $13.60. The business’s 50-day moving average is $4.93 and its 200 day moving average is $4.58.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. As a group, equities research analysts anticipate that Omeros Corporation will post -3.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on OMER shares. HC Wainwright raised their price objective on Omeros from $9.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. WBB Securities reaffirmed a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.50.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.